Don't Miss These "Diamond in the Rough" Stocks 💎

Don't miss these red-hot stocks... [Image](www.elitetrade.club) Good Morning! Hey, guys and gals. It's Chris from Elite Trade Club, here to give you the day's premarket trading news. Happy Monday! Today is July 11th. Let's get ready to trade! Markets 📈 Stocks fell on Friday after a stronger-than-expected June jobs report reignited investors' fears of another steep rate hike in July. The S&P 500 lost 0.1% on the session, and the Dow fell 0.2%. The Nasdaq edged 0.1%higher, and the Russell 2K closed flat. Today, markets are on pace to kick off the week on a down note. S&P 500 futures are currently down 0.5% Sponsored [Don't Miss These "Diamond in the Rough" Stocks]( 💎 These 5 small, under-the-radar stocks could be set to soar after their upcoming quarterly earnings. There could be sharp gains in share prices on the heels of these announcements. And, you can still get onboard for cheap. [Here Are Our TOP 5 Microcap Stocks]( Premarket Highlights 🔎 - Twitter shares are tumbling after Elon Musk announced he would pull out of his deal to acquire the company. - Europe's Nord Stream Pipeline shut down for scheduled maintenance today, and the stoppage could have an impact on oil and natural gas prices. What to Watch Today 👀 Earnings Bellwethers This week, earnings reports from PepsiCo, Delta Air Lines, and others could shed some light on how inflation and a tight job market impacted corporations and consumers over the most recent quarter. The reporting companies' earnings guidance and forward-looking forecasts should also give us some insights into what they expect for the months ahead. International 🌍 Asia Japan's Nikkei 225 gained 1.1% overnight, while Hong Kong's Hang Seng Composite sold off for 2.8%. Mainland China's Shanghai Composite tumbled 1.3%, and Australia's ASX 200 ended its session down 1.1%. Europe European markets are in the red, with Germany's DAX down 0.8%. France's CAC 40 is showing a 0.6% loss, and the Euro Stoxx 600 is down 0.3%. Major Earnings 💰 - E2open [ETWO] ... PM - The Greenbrier Companies [GBX] ... AM - AZZ [AZZ] ... AM Economy 🏗 - 3-year inflation expectations [June] ... 11a Running Hot 🔥 Gainers - Inpixion [INPX] >> +13.5% - Phunware [PHUN] >> +21.3% - COMSovereign Holding [COMS] >> +24.4% Decliners - ContraFect Corp [ENJY] >> (18.6%) - Scopus [AREB] >> (14.0%) - Prime Neurosciences [UPST] >> (12.3%) Digital World Acquisition Corp [DWAC] - Last Close: $24.52 Investors see bad news for Twitter as good news for Digital World Acquisition Corp. The SPAC, which has agreed to take former President Donald Trump's TRUTH Social media platform public, is up following the potential collapse of Elon Musk's deal to buy Twitter. After Musk announced he intended to pull out of the deal last Friday, Pres. Trump released a statement saying, "THE TWITTER DEAL IS DEAD, LONG LIVE THE TRUTH,” referring to his TRUTH Social platform. Twitter is pursuing legal action to force Musk to make the deal, and the company has said it is confident it will succeed in court. It's unclear how the legal drama will shake out at this point. Regardless, investors see the Twitter turmoil as a win for TRUTH Social. Shares of DWAC are up 16.4% in today's premarket, and DWAC warrants are up 34.0%. Our Take: If the Musk-Twitter deal collapses, it could be good news for TRUTH Social. Conservatives and right-leaning voices would be less inclined to switch over to Trump's platform if Musk reformed Twitter's restrictive content moderation policies to be more tolerant of their viewpoints. Pliant Therapeutics [PLRX] - Last Close: $8.88 Strong drug data is boosting shares of Pliant Therapeutics in today's premarket. The clinical-stage biotech announced this morning that a Phase 2a trial of PLN-74809 to treat idiopathic pulmonary fibrosis patients met its primary and secondary endpoints. Clinical data shows the drug was well-tolerated over a 12-week treatment period, and it had a favorable pharmacokinetic profile, according to a company statement. The drug also demonstrated beneficial treatment effects of forced vital capacity and quantitative lung fibrosis imaging in comparison to placebo. Pliant says it expects to another report on interim 12-week data from a 320-mg cohort of the study early next year. PLRX is one of this morning's top-performing stocks with a 45.2% gain on high volume. Our Take: This is good news for Pliant, but an FDA approval is still a ways down the road. It's not clear yet if the drug will get that far, but ongoing drug trials leave the potential for future catalysts. Nyxoah SA [NYXH] - Last Close: $7.78 Nyxoah is moving higher on news of a favorable regulatory decision. The medical technology company announced this morning that the US Food & Drug Administration has approved an investigational device exemption that clears the way for a clinical trial assessing its Genio system for moderate-to-severe obstructive sleep apnea. The Belgium-based company says it plans to begin implanting the device in as many as 106 patients by the fourth quarter. The study will analyze and assess the device's effect on patients' apnea-hypopnea index and oxygen desaturation index at 12 months. News of the FDA green light rallied NYXH to a 22.4% gain ahead of today's open. Our Take: This tiny med-tech stock could have significant upside if it can break through into the big leagues, but it should be treated as a speculative trade for the foreseeable future. Iterum Therapeutics [ITRM] - Last Close: $0.24 Iterum Therapeutics is taking off on the heels of a major announcement. The clinical-stage pharma firm said today that it had reached an agreement with the US FDA under the special protocol assessment, or "SPA", on the design, endpoints, and analysis of a Phase 3 clinical trial for its oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections. The agreement clears the way for Iterum to begin enrolling up to 1,966 patients for a large-scale Phase 3 study in the fourth quarter of 2022. If the drug makes it through the Phase 3 study, it could be on course for a full FDA approval and, eventually, a commercial launch. ITRM is powering to the top of today's premarket charts with a 45.2% gain on active trading volume. Our Take: This penny stock could see more big gains if the drug makes it through Phase 3 trials, but it might be too early to make a play just yet. However, it could be worth watching once the pivotal study wraps up. Invite Your Friends to Join Elite Trade Club and [Start Earning Valuable Rewards Now!](elitetrade.club/referral/?email={EMAIL}) [Image](elitetrade.club/referral/?email={EMAIL}) That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](